The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
21 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,173,666 in first-year total cost, median $300,000.
Most frequent study sections
- Special Emphasis Panel[ZRG1 IDM-V (12)]6
- Special Emphasis Panel[ZRG1 IDM-U (10)]5
- Special Emphasis Panel[ZRG1 IMM-N (12)]4
- Special Emphasis Panel[ZRG1 DKUS-A (10)]1
- Special Emphasis Panel[ZRG1 ETTN-M (11)]1
Most frequent institutions
- L2 DIAGNOSTICS, LLC2
- MICROBIOTIX, INC2
- NOVALEX THERAPEUTICS, INC.2
- BIOPEPTIDES, INC.1
- CLINICAL SENSORS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Preclinical development of novel small molecule malaria drugs that overcome drug2R42AI094959-03A1 | PEYTON, DAVID H | DESIGNMEDIX, INC., OR | $989,081 | ZRG1 |
| 2014 | Antigen Detection assay for the Diagnosis of Melioidosis2R42AI102482-03 | AUCOIN, DAVID PHOUGHTON, RAYMOND | INBIOS INTERNATIONAL, INC., WA | $621,080 | ZRG1 |
| 2014 | New heterocyclic inhibitors of filoviruses1R41AI110091-01 | RONG, LIJUN | MICROBIOTIX, INC, MA | $300,000 | ZRG1 |
| 2014 | Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens1R41AI108029-01A1 | GEISBERG, MARK | SILVER LAKE RESEARCH CORPORATION, CA | $300,000 | ZRG1 |
| 2014 | New small molecule inhibitors of arenaviruses1R41AI112045-01 | RONG, LIJUN | MICROBIOTIX, INC, MA | $300,000 | ZRG1 |
| 2014 | Nitric Oxide Microfluidic Sensor1R41AI112064-01 | SCHOENFISCH, MARK H | CLINICAL SENSORS, INC., NC | $300,000 | ZRG1 |
| 2014 | Development of an Antigen Capture Assay for Babesia microti1R41AI108006-01A1 | DATTWYLER, RAYMOND JAMESMORDUE, DANA G | BIOPEPTIDES, INC., CT | $300,000 | ZRG1 |
| 2014 | Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors1R41AI112114-01 | JOHNSON, MICHAEL E.LEE, HYUN | NOVALEX THERAPEUTICS, INC., IL | $300,000 | ZRG1 |
| 2014 | Rapid, Accurate, and Low-Cost Stool Clostridium difficile Genetic Test1R41AI112224-01 | SHIH, WAN Y. | LENIMA FIELD DIAGNOSTICS, LLC, PA | $300,000 | ZRG1 |
| 2014 | Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology1R41AI109911-01A1 | COLEMAN, JOHN ROBERT | CODAGENIX, INC., NY | $300,000 | ZRG1 |
| 2014 | Development of a novel highly effective influenza vaccine1R41AI109925-01A1 | BILSEL, PAMUKSARAWAR, SALLY R. | FLUGEN, INC., WI | $300,000 | ZRG1 |
| 2014 | RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis1R41AI114064-01 | KO, ALBERT ICKSANGLEDIZET, MICHELPAL, UTPAL | L2 DIAGNOSTICS, LLC, CT | $300,000 | ZRG1 |
| 2014 | A Multivalent Lyme Disease Vaccine Targeting Tick-Host-Pathogen Interactions1R41AI112133-01 | NARASIMHAN, SUKANYA | L2 DIAGNOSTICS, LLC, CT | $299,998 | ZRG1 |
| 2014 | CMV Vectored Herpes Simplex Vaccine1R41AI109927-01A1 | STREBLOW, DANIEL N | TOMEGAVAX, INC., OR | $299,863 | ZRG1 |
| 2014 | Low-Cost Instrument-free Point-of-care Platform for Multiplexed Chlamydia Diagnos1R41AI114068-01 | DEAN, DEBORAH ANNEDIMOV, IVAN | LUCIRA HEALTH, INC, CA | $299,748 | ZRG1 |
| 2014 | Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum1R41AI114049-01 | AUCOIN, DAVID PEMBERS, MONICA E | DXDISCOVERY, INC., NV | $298,958 | ZRG1 |
| 2014 | Anti-Pseudomonas Immunotherapy and Targeted Drug Delivery1R41AI114252-01 | KAUFMANN, GUNNAR JOERG FLORIS | SORRENTO THERAPEUTICS, INC., CA | $298,668 | ZRG1 |
| 2014 | Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility1R41AI110090-01A1 | CHRISTIE, SHAHILA MEHBOOBJOHNSON, MICHAEL E. | NOVALEX THERAPEUTICS, INC., IL | $298,502 | ZRG1 |
| 2014 | Development of Peptide Antibiotic Nucleic Acids1R41AI114114-01 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $295,755 | ZRG1 |
| 2014 | A molecularly targeted pre- and post-exposure vaccine for anthrax1R41AI106153-01A1 | OSCHERWITZ, JONWHITACRE, DAVID C | VLP BIOTECH, INC., CA | $260,205 | ZRG1 |
| 2014 | Developing a new treatment for MS: Controlling CD40 in EAE1R41AI113977-01 | WAGNER, DAVID H. | OP-T-MUNE, INC., CO | $211,808 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.